Pipeline Therapeutics and Janssen partner for neuroscience therapy
19 Apr 2023
Phase 1License out/inPhase 2
Preview
Source: Pharmaceutical Technology
Photomicrograph of a demyelinating multiple sclerosis lesion. Credit: Marvin 101 / commons.wikimedia.org.
Pipeline Therapeutics and Janssen Pharmaceutical have signed a global licence and development agreement for PIPE-307 to treat disorders of the nervous system.
An oral, selective, muscarinic M1 receptor antagonistmuscarinic M1 receptor antagonist, PIPE-307, has been designed to drive oligodendrocyte precursor cells’ mutations into oligodendrocytes that produce myelin.
PIPE-307 has already been evaluated in two Phase I clinical trials in healthy patients, and has also received Food and Drug Administration (FDA) clearance as an investigational new drug (IND) to commence its clinical development in patients with relapsing-remitting multiple sclerosis (RRMS).
Upon completion of the transaction, Pipeline will also receive an equity investment of up to $25m separately from Johnson & Johnson Innovation, as well as up to $25m in equity investments from the existing investors of the company.
Pipeline will receive $1bn in clinical, regulatory and commercial milestones, along with royalty payments.
Pipeline president and CEO Carmine Stengone said: “We are excited to announce this agreement, which is aligned with our vision to maximise the reach of PIPE-307 through clinical evaluation in RRMS and other neurological disorders.
“In addition, we are pleased that we will strengthen our financial position with the upfront payment from this agreement and equity investments from existing and new investors, enabling us to extend our runway and to continue advancing our portfolio in small molecule neuroregeneration.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.